kidney disease Archives

The study team included, from left, Raymond Harris, MD, J.P. Arroyo, MD, PhD, and Gautam Bhave, MD, PhD.

VUMC researchers upend dogma about vasopressin production

Jan. 5, 2023—Vanderbilt investigators have discovered that vasopressin, which has long been thought to be produced only in the brain, is also produced in the kidney.

Craig Brooks, PhD, and colleagues are studying a molecular mechanism that promotes chronic kidney disease following kidney injury. (photo by Erin O. Smith)

Novel therapeutic target identified for chronic kidney disease

Dec. 15, 2022—Vanderbilt investigators have discovered a molecular mechanism that promotes chronic kidney disease following kidney injury.

Nephrology society lauds Bock’s research on kidney development

Dec. 15, 2022—Vanderbilt's Fabian Bock, MD, PhD, won two awards at the Basic Research Forum for Emerging Kidney Scientists, presented virtually by the American Society of Nephrology and American Physiological Society.

Terker selected as VUMC Discovery Scholar in Health and Medicine

Oct. 27, 2022— by Bill Snyder Andrew Terker, MD, PhD, assistant professor of Medicine in the Division of Nephrology and Hypertension at Vanderbilt University Medical Center, has been selected as the 2022 VUMC Discovery Scholar in Health and Medicine. The Discovery Scholars program was launched in 2020 with funding from the Brock Family Directorship in Career Development...

Meena Madhur, MD, PhD, Matthew Alexander, MD, PhD, and colleagues are studying how a common genetic change impacts the development of inflammation and high blood pressure.

Study sheds light on the development of inflammation, high blood pressure and resulting kidney damage

Oct. 20, 2022—by Bill Snyder Researchers at Vanderbilt University Medical Center have found that the change in a single letter of the genetic code promotes, in a mouse model, the development of inflammation, high blood pressure and resulting kidney damage. Their findings, featured Oct. 14 on the cover of Circulation Research, suggest that targeting inflammatory cytokines, signaling...

From left, Raymond C. Harris, MD, Shirong Cao, MD, PhD, Ming-Zhi Zhang, MD, MSc, and colleagues are studying the role of inflammation in obesity.

Study sheds light on the dark side of obesity

May. 12, 2022—Vanderbilt research that promotes the anti-inflammatory pathway in macrophages could also reduce some of the bad side effects of obesity.

Corina Borza, PhD, left, Ambra Pozzi, PhD, and colleagues are studying a certain cell surface receptor’s role in the process that leads to kidney failure.

VUMC study raises hope for improving treatment of kidney disease

Feb. 2, 2022—Vanderbilt research has revealed an important mechanism in the kidney by which a cell surface receptor known as DDR1 fans the flames of inflammation and fibrosis that ultimately lead to kidney failure.

Accelerating podocyte production

Feb. 1, 2022—A new method developed by Vanderbilt researchers to generate kidney cells from stem cells offers a faster and less expensive way to make these valuable tools for studying kidney diseases.

Roy Zent, MBBCh, PhD, left, Fabian Bock, MD, PhD, and colleagues are studying the factors involved in the maintenance and integrity of the kidney collecting duct.

Harrison Society researcher discovers key regulator of kidney cell structure

Nov. 4, 2021—New research from Vanderbilt could aid efforts to promote kidney regeneration after injury or to develop engineered organs.

Gene expression in diabetic nephropathy

Aug. 5, 2021—Vanderbilt researchers are looking to mRNA populations in podocytes — kidney cells that help filter blood — to help identify potential targets for treating diabetic kidney disease.

Spirituality may help reduce end-stage kidney disease risk

Mar. 25, 2021—Researchers from Vanderbilt’s Division of Nephrology and Hypertension have identified an under-studied characteristic that may have a protective effect on end-stage kidney disease (ESKD) risk among vulnerable populations.

Clue to diabetic kidney disease

Oct. 5, 2020—Vanderbilt researchers have identified a signaling pathway that promotes kidney fibrosis in patients with diabetes — and that could be targeted with an existing approved medication.